Background Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract associated with altered composition of the gut microbiota. Lactobacillus reuteri BR11 (BR11) has recently been reported to reduce the severity of experimental IBD because of its probiotic properties possibly attributed to a mechanism of thiol production via its unique cysteine/cystine-transport system. Aim We compared BR11 and a BR11 mutant deficient in the cystine-uptake system (PNG201), for their capacity to reduce the severity of experimental colitis. Methods Male Sprague-Dawley rats (n = 8 per group) were gavaged (1 ml/day) with skim milk, BR11 or PNG201 (1 9 10 9 CFU/ml) for 12 days. Rats consumed either water or 2% dextran sulfate sodium in drinking water from days 6 to 12 to induce colitis. Metabolism data, disease activity index, intestinal mucin profile, and histological analyses were assessed and compared by ANOVA.
Introduction
The term ''inflammatory bowel disease'' (IBD) is used to denote an assemblage of chronic intestinal inflammatory disorders with an incidence of approximately 1 in 9-10,000 [1] . The etiology of IBD is not fully understood. However, apart from genetic predisposition, contributing factors include environmental, immunological, and microbial effects [2] . The pathology of IBD is characterized by damage to the gastrointestinal epithelium and mucosa, resulting in ulceration, inflammation, and hemorrhage.
Because current pharmaceutical treatment options for IBD are relatively ineffective, investigations into alternatives have increased. Probiotics, strains of living bacteria that have positive effects when administered in sufficient quantities [3] , are one such option. A wide array of probiotic strains, and combinations thereof, have been investigated, with different success, in attempts to identify the most effective treatment options for IBD, and also to better understand their modes of action [4] [5] [6] . These bacterial strains are believed to exert their beneficence through a number of different mechanisms, most of which are not completely understood [7, 8] . These mechanisms include competition with pathogens, modulation of the intestinal immune system, maintaining homeostasis of the intestinal epithelium, promoting crypt cell proliferation, inhibition of cell apoptosis, and reduction of pro-inflammatory cytokine expression [4, 7, [9] [10] [11] [12] .
Lactobacillus reuteri BR11 (BR11) (formerly Lactobacillus fermentum, BR11) is a bacterial strain with unique antioxidant properties [13] that has shown promise in the treatment of experimental colitis [14] . It has been proposed that the efficacy of BR11 is mediated through its unique cystine-transport system [13, 15, 16] . This transport system is responsible for transporting exogenous cystine into the bacterial cell and expelling the thiol products, which diminish the effects of oxidative stress by detoxifying reactive oxygen species present [17] . Oxidative stress is one of the main factors affecting intestinal injury in IBD [18] , with recent studies suggesting that probiotic administration can attenuate oxidative stress in rats [19] . The uptake system of L. reuteri BR11 comprises a high-affinity cystine-binding protein termed cystine uptake C (CyuC), a component of the ATP binding cassette cystine-transport system [20] . In order to determine the role of this unique system, the cyuC gene was inactivated using homologous recombination to produce an L. reuteri mutant (PNG201) deficient in cystine uptake [13, 21] . Utilizing a rat model of colitis induced by ingesting dextran sulfate sodium (DSS) it was hypothesized that elimination of the CyuC protein, which effectively inactivates the entire transport of cystine, would result in a decreased ability of the bacteria to prevent colonic injury.
Materials and Methods

Bacterial Preparations
Lactobacillus reuteri BR11, and the CyuC deficient strain PNG201, were both kind gifts from Professor Philip Giffard and Dr Mark Turner, Queensland University of Technology (Queensland, Australia). L. reuteri BR11, originally isolated from the vaginal tract of a guinea pig [22] , and L. reuteri PNG201, a CyuC-deficient mutant developed using homologous recombination [13] , were grown on Mann Rogosa Sharp (MRS) agar and broths (Oxoid, Hampshire, UK) with or without the antibiotic, erythromycin (10 lg/ml). As PNG201 was developed to be resistant to erythromycin, culturing the mutant in the presence of this antibiotic ensured the mutant had not reverted to wild-type, and confirmed the specimen was uncontaminated. Both were incubated under anaerobic conditions at 37°C. The bacteria were grown to concentrations of approximately 1 9 10 9 colony forming units (CFU)/ml, dissolved in 10% skim milk powder, and stored at -20°C until required.
Animal Trial
The animal trial was performed in compliance with The Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and was approved by the Animal Care and Ethics Committee of the University of Adelaide. Male Sprague-Dawley rats (n = 48; 120-160 g) were housed individually in metabolism cages (Tecniplast, PA, USA) at a room temperature of 22°C with a 12 light:dark cycle. Throughout the duration of the trial the rats had ad libitum access to a standard 18% casein diet [23] and water. All animals were acclimatized for two days before experimentation. Metabolism data including body weight, food and water intake, and fecal and urine output were monitored and measured daily.
Rats were randomly allocated to one of six treatment groups (n = 8 rats/treatment); Water ? Vehicle, Water ? BR11, Water ? PNG201, dextran sulfate sodium (DSS) ? Vehicle, DSS ? BR11, or DSS ? PNG201. L. reuteri BR11 solution (1 ml) or vehicle (skim milk) was administered once daily via oral gavage from days 1 to 12. Between days 6 and 12, experimental colitis was induced by addition of 2% DSS (ICN Biomedical, CA, USA) to the drinking water.
Disease severity was monitored daily, on the basis of a disease activity index (DAI) scoring overall animal condition, weight loss, stool consistency, and rectal bleeding, on a scale from 0 to 3 for each, between days 7 and 12 (0 being healthy and 3 being severely affected) [24] . On day 12, all rats were sacrificed by carbon dioxide asphyxiation and cervical dislocation before dissection. After sacrifice, the lengths of the gastrointestinal organs were measured unstretched, and all internal organs were emptied of contents, if necessary, and weighed. Separate 2-cm segments of proximal and distal colon were removed and placed in 10% buffered formalin for histological analysis and 4 cm segments were snap-frozen in liquid nitrogen and stored at -80°C for biochemical analysis.
Histological Analysis
Segments (2 cm) of the proximal and distal colon were processed routinely and embedded in paraffin wax. Sections (4 lm) were then cut and stained with hematoxylin and eosin. Severity of intestinal damage was assessed by quantitative analysis of surface enterocyte disruption, goblet cell numbers, crypt disruption, crypt abscess formation, polymorphonuclear cell infiltration, submucosal thickening, and submuscularis externa thickening [25] . A score of 0 (unaffected) to 3 (severe damage) was recorded for each of these to give an overall disease severity score, which was expressed as a median score (range). Both crypt loss and lengthening are common features of the DSS-colitis model [26] . Measurements of crypt depth in the proximal and distal colon were also determined, using 40 crypts per tissue section per rat to obtain a mean value [27] . Crypt area was calculated for the distal colon using three tissue sections per rat to obtain a mean value. All analyses were performed in a blinded fashion, using an Olympus (Tokyo, Japan) BH-2 light microscope with a Sony (Tokyo, Japan) digital camera and Image Pro Plus software version 4.5.1.27 (Media Cybernetics, MD, USA).
Mucin Characterization
The heterogeneous oligosaccharide chains of mucin glycoproteins provide potential binding sites for both commensal and pathogenic organisms, and may perform a defensive role as a protective barrier during periods of mucosal injury [28] . Derangement of this barrier has been linked to the pathophysiology of ulcerative colitis [29] . Colonic sections from each animal were stained with periodic acid-Schiff (PAS) [30] . Sections were subjected to mild acid hydrolysis to eliminate the contribution of sialic acid residues before PAS staining. Sections were immersed in periodic acid solution (Sigma, St Louis, MO, USA) for 20 min, washed, and immersed in Schiff's Reagent (Sigma) for a further 20 min. Sections were rinsed in tap water for 10 min, dehydrated, and mounted in Entellan (ProSciTech, Kirwan, Queensland, Australia). Stained sections were examined by light microscopy with an Olympus CX41 microscope using a 209 objective and digital color images (super high quality; 2,080 9 1,544 pixels) captured using an Olympus U-CAMD3 wide-zoom camera. Image analysis software analySIS FIVE (Olympus Soft Imaging Solutions, Germany) was used for measurement of each of the stained sections. The number of goblet cells per unit of epithelial area (mm 2 ) was calculated.
Statistical Analysis
Statistical analysis was performed by use of SPSS 15.0 software (SPSS, Chicago, IL, USA). Histological damage severity was expressed as a median value whereas all other data were expressed as mean ± SEM. Comparisons of data between treatment groups were performed by use of oneway ANOVA, with a Tukey's post-hoc test. DAI data were analyzed using repeated measure ANOVA with a Tukey's post-hoc test. Qualitative analysis of histology data was performed by use of a Kruskal-Wallis test. For all analyses, P \ 0.05 was considered significant.
Results
Metabolism Data
No significant difference (P [ 0.05) in weight gain was evident among the water or DSS-treated groups, except for DSS ? PNG201 in which the weight gain was significantly reduced (P \ 0.05) compared with healthy control rats (Table 1) . Food and water consumption remained similar (P [ 0.05) across the groups over the course of the experimental period, with no effect of treatments. Although output of urine and feces were not significantly different in the water-treated groups (P [ 0.05, Table 1 ), DSS consumption increased fecal production (P \ 0.05) for the BR11 (29%) and PNG201 (25%)-treated groups compared with healthy controls (water ? skim milk). Urine output for all DSS treated animals decreased (P \ 0.001) remarkably (by *40%) compared with water controls.
Disease Activity Index (DAI)
An increase in DAI is usually evident in the DSS-induced model of colitis [14] . On days 8, 10, and 11 DAI was significantly greater (P \ 0.05) in DSS ? PNG201 than for healthy controls. On day 12, DAI was significantly greater for DSS-treated rats receiving BR11 than for healthy control rats, with DSS ? PNG201 highly significant (P \ 0.001) compared with healthy controls (Fig. 1) .
Organ Weights and Lengths
Organ weights were expressed as a proportion of total body weight to correct for differences in body weight. No significant differences (P [ 0.05) were observed in the fractional weights of any of the visceral organs (heart, lungs, left kidney, right kidney, liver, spleen, and thymus) among the treatment groups as a result of BR11, PNG201, or DSS administration compared with normal controls (data not shown). Similarly, administration of neither bacterial strain nor DSS failed to have any significant effect (P [ 0.05) on the lengths of the duodenum and small intestine. However, the length of the colon was significantly reduced (P \ 0.05) in DSS-treated rats receiving BR11 (18%) and PNG201 (20%) compared with healthy controls (Table 2 ). This was accompanied by a significantly greater (28%; P \ 0.05) weight of the colon in DSS-treated rats receiving PNG201 compared with water-drinking controls. Nonetheless, weights of all other gastrointestinal organs (stomach, duodenum, small intestine, and cecum) were not altered significantly in any of the treatment groups (Table 2) .
Histological Analysis
The damage severity score in the proximal and distal colon was significantly greater (P \ 0.001) after DSS consumption than for healthy controls (Table 3) . Interestingly, the severity scoring for DSS ? PNG201 was significantly greater (P \ 0.05) than for DSS ? BR11 in the distal colon. No significant (P [ 0.05) effect on crypt depth in the distal colon was exerted by either bacterial strain (BR11: 215 ± 24 lm, PNG201: 198 ± 23 lm) or DSS consumption (252 ± 11 lm) compared with the watertreated controls (210 ± 11 lm). Although crypt area in the distal colon was not affected by BR11 or PNG201 administration in healthy animals, it was significantly (P \ 0.05) reduced in the DSS control and DSS ? PNG201 compared with the water-treated controls (Fig. 2 
Discussion
Although the novel antioxidant mechanism of L. reuteri BR11 has been examined extensively in vitro, the contribution of the cystine uptake transport system to probiotic activity has not been investigated in vivo. BR11 has been tested for therapeutic efficacy primarily using the DSScolitis model. As such, we utilized this model to investigate Fecal output (g) 11.2 ± 0.3 11.6 ± 0.7 11.3 ± 0.6 13.6 ± 0.6 14.4 ± 0.8* 14.0 ± 0.9* Urine output (ml) 129 ± 8 123 ± 9 129 ± 7 7 7 ± 3*** 79 ± 4*** 78 ± 2*** n = 8 rats/treatment. Data are expressed as mean ± SEM. Skim milk (SM) was used as vehicle * Indicates P \ 0.05 compared with water ? SM *** Indicates P \ 0.001 compared with water ? SM the role of the cystine-uptake system to better define its contribution to the effects of BR11. In this study, DSS consumption resulted in moderate damage to the proximal and distal colon, observed through histological scoring, increased fecal production, and a progressively increasing DAI score during the period of DSS consumption, including the presence of diarrhea and rectal bleeding in later stages. Consumption of DSS is known to cause histological changes in the colon, including an elevated damage severity score, lengthening of crypts, and crypt loss [26] , often in conjunction with significant shortening of the colon [31] . Crypt lengthening and crypt loss are also commonly observed indicators of DSSinduced colitis [32] , however, only crypt loss was observed in this study. Lengthening of crypts is believed to be a compensatory mechanism to maximize absorptive function during periods of damage and repair, the absence of this feature in our study may therefore have been related to the severity of DSS-induced damage or the timing of the measurement.
In this study, administration of BR11 did not have any significant effect compared with the DSS-treated colitic control, whereas administration of PNG201 caused minimal changes compared with wild-type BR11, namely, an elevated intestinal severity score in the distal colon. On the basis of this finding, we can speculate that the presence or absence of CyuC has little effect on the mode of action of BR11 in our setting. It should be noted, however, that increased colon weight, reduced body weight, and reduced % relative to body weight) ± SEM. SM was used as vehicle * Indicates P \ 0.05 significance to water ? SM Table 3 Effect of L. reuteri BR11 and its mutant PNG201 on histological damage severity scores in the proximal colon of rats after DSS administration crypt area were observed for rats treated with PNG201 compared with healthy control rats, results that were not obtained for the BR11-treated rats. This may indicate that the PNG201-treated rats were affected by DSS to a greater extent than their BR11-treated counterparts. Because, for many of the measurements, the effects for the DSS-colitis control group failed to reach significance compared with the healthy controls, it could be surmised that the challenge provided by the DSS in this trial was reflective of very lowgrade colitis. As such, the significance of the cystineuptake system to the possible probiotic properties of BR11 could not be determined with certainty. As the severity of colitis was relatively low, it was difficult to discern whether the bacterial strains acted as hypothesized, with BR11 partially normalizing crypt area, but failing to reduce overall damage severity in the colon. As responses to DSS are dose-dependent [33] , in future studies a higher dose of DSS in the drinking water could induce colitis of greater severity to fully evaluate the role of the cystine-uptake system. Previously, appropriate disease severity was achieved by administering DSS at 2% to Sprague-Dawley rats for 7 days [14] . This DSS concentration was consistent with that in our study; however, rats were exposed to DSS for 6 days only. Although some animals responded as expected, with progressively worsening diarrhea and anal bleeding, others displayed no overt clinical signs of disease for the duration of the animal trial; observation of histological sections proved they were affected, however.
Although in this study BR11 was able to partially prevent crypt loss, there was no significant ameliorating effect on any of the other results. To this end, both the BR11 wildtype and the PNG201 mutant failed to achieve statistical significance compared with the colitis control for all measurements. Probiotics, unlike conventional treatments, are living organisms, and thus their effects within the body can be variable. The reduced bioactivity of the BR11 wild-type in this study was in contrast with the study conducted by Geier et al. [14] , in which BR11 was found to reduce disease activity and histological severity, prevent colon shortening, and normalize weight gain and food intake, all of which were significantly affected in the DSS-treated controls. A possible reason for these differences may have been the concentration of bacteria administered to the animals. In the study by Geier et al. [14] the bacteria were grown to a concentration of 1-2 9 10 10 CFU/ml whereas in our study bacterial concentrations were a factor of ten lower (1 9 10 9 CFU/ml). In support of this hypothesis, animal studies using BR11 in a model of 5-FU-induced intestinal mucositis have failed to achieve beneficial results using lower or similar BR11 concentrations. One study comparing three different bacterial strains using concentrations of 1 9 10 6 CFU/ml failed to improve any of the indicators assessed, despite previous studies indicating their potential [34] . Another study investigating BR11 at concentrations of 1 9 10 9 CFU/ml, also failed to achieve any significant beneficial results [35] . However, it should be noted that a higher DSS dose (3%) was also used by Geier et al. [35] .
The lack of efficacy observed in other studies indicates that BR11 may be an effective probiotic at high (*1 9 10 10 CFU/ml) concentrations only, which suggests the concentration of bacteria in this study may have been insufficient. Additionally, any decreased function in the PNG201 mutant would only be observed at higher concentrations. As such, future studies could benefit from administration of higher concentrations of BR11 and the PNG201 mutant strain. Although, it was routinely cultured in the presence of erythromycin, it is still possible the PNG201 mutant may have reverted back to the wild-type in the animals in the absence of erythromycin selection. In future studies, culturing the bacterial population in the feces, on MRS agar ? erythromycin, could be used to monitor the stability and/or survival of the mutant.
In conclusion, in this study, neither the wild-type BR11 nor a CyuC deficient strain of L. reuteri could prevent the development of experimental colitis in rats. However, rats administered the PNG201 BR11 mutant strain displayed some indications of minor exacerbation of colitis compared with the wild-type strain. Nevertheless, the challenge provided by the DSS, and possibly the concentration of the bacterial treatments, may have been sub-optimum to provide conclusive evidence regarding the contribution of the cystine-uptake system to the mechanism of action of BR11. Further studies using BR11 are required to clarify the conflicting results observed in previous studies of BR11 in the contexts of colitis and mucositis to definitively classify BR11 as a probiotic.
